AR and neoplasm: In castration-resistant orthotopic LNCaP xenograft models, IRC117539 treatment did not significantly decrease AR protein levels (as determined by immunohistochemistry and ELISA, Fig 5C) and neither diminished tumor weight nor was it capable of reducing prostate specific antigen (PSA) levels in peripheral blood (Fig S7).